Results 111 to 120 of about 1,816 (199)

Safety and effectiveness of the fluocinolone acetonide intravitreal implant (ILUVIEN): 3-year results from the European IRISS registry study. [PDF]

Br J Ophthalmol, 2023
Khoramnia R, Peto T, Koch F, Taylor SR, Castro de Sousa JP, Hill L, Bailey C, Chakravarthy U, ILUVIEN Registry Safety Study (IRISS) Investigators Group.   +8 more
europepmc   +1 more source

Post-cataract outcomes in patients with noninfectious posterior uveitis treated with the fluocinolone acetonide intravitreal implant

Clinical Ophthalmology, 2012
John D Sheppard Jr1, Quan Dong Nguyen2, Dale W Usner3, Timothy L Comstock3, for the Fluocinolone Acetonide Uveitis Study Group1Eastern Virginia Medical School, Norfolk, VA, USA; 2Wilmer Ophthalmological Institute, Johns Hopkins University, Baltimore, MD,
Sheppard Jr JD, Nguyen QD, Usner DW, Comstock TL; Fluocinolone Acetonide Uveitis Study Group   +3 more
doaj  

Retinal Morpho-Functional Changes Following 0.19 mg Fluocinolone Acetonide Intravitreal Implant for Chronic Diabetic Macular Edema. [PDF]

Adv Ther, 2021
Minnella AM, Picardi SM, Maceroni M, Albanesi F, De Siena E, Placidi G, Caputo CG, De Vico U, Rizzo S, Falsini B.   +9 more
europepmc   +1 more source

Novel Intraocular Therapy in Non-infectious Uveitis of the Posterior Segment of the Eye [PDF]

, 2013
This article reviews the new clinically relevant data regarding the intraocular treatment of non-infectious uveitis. Triamcinolone acetonide is the most commonly used intravitreal corticosteroid for treatment of uveitis and uveitic macular oedema.
Mikhail, Michael, Sallam, Ahmed
core   +1 more source

Fluocinolone acetonide 0.2 μg/day intravitreal implant in non-infectious uveitis affecting the posterior segment: EU expert user panel consensus-based clinical recommendations. [PDF]

Background: Non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) is an inflammatory disease, which can significantly impair visual acuity if not adequately treated.
Bodaghi Bahram, Burke Tomás, Devonport Helen, Heinz Carsten, Kodjikian Laurent, Llorenç Víctor, Miserocchi Elisabetta, Nogueira Vanda, Pavesio Carlos, Pleyer Uwe   +9 more
core   +1 more source

Intravitreal Dexamethasone Implant as an Adjunct Weapon for Severe and Refractory Uveitis in Behçet's Disease [PDF]

, 2017
Background: The evidence on the use of dexamethasone implants in the treatment of Behçet’s disease (BD)-related uveitis is limited to a few cases. Objectives: To evaluate the efficacy of dexamethasone implants on ocular functional, morphological, and ...
Bacherini, Daniela, Cantarini, Luca, Emmi, Giacomo, Fabiani, Claudia, Franceschini, Rossella, Frediani, Bruno, GUERRIERO, Silvana, IANNONE, Florenzo, LOPALCO, GIUSEPPE, Marco Tosi, Gian, Rigante, Donato, Vannozzi, Lorenzo   +11 more
core  

Non-infectious uveitis affecting the posterior segment treated with fluocinolone acetonide intravitreal implant: 3-year fellow eye analysis. [PDF]

Eye (Lond), 2022
Pavesio C, Heinz C.
europepmc   +1 more source

Gestione dell'edema maculare diabetico [PDF]

, 2011
Gestione dell'edema maculare diabetico, nuove ...
CAPUTO, SILVESTRO
core  

Comment on ’Effectiveness of 190 μg Fluocinolone Acetonide versus 700 μg Dexamethasone Intravitreal Implants in Diabetic Macular Edema Using the Area-Under-the-Curve Method: The CONSTANT Analysis’ [Response to Letter]

Clinical Ophthalmology, 2020
Javier Zarranz-Ventura,1 Joshua O Mali2 1Institut Clínic d’Oftalmología (ICOF), Hospital Clinic, Barcelona, Spain; 2The Eye Associates, Sarasota, FL, USACorrespondence: Javier Zarranz-VenturaInstitut Clínic d’Oftalmolog ...
Zarranz-Ventura J, Mali JO
doaj  

Early adoption of the fluocinolone acetonide (FAc) intravitreal implant in patients with persistent or recurrent diabetic macular edema (DME)

International Medical Case Reports Journal, 2019
Jessica D McCluskey, Paul L Kaufman, Kathy Wynne, Gregory LewisDepartment of Ophthalmology, Thomas Eye Group, Atlanta, GA, USAObjective: To assess long-term outcomes for effectiveness, safety, and treatment burden after injection of 0.2 μg/day ...
McCluskey JD, Kaufman PL, Wynne K, Lewis G   +3 more
doaj